Analyst Reco. Novavax, Inc.

Equities

NVAX

US6700024010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
11.9 ^USD	-5.18%		-6.00%	+147.92%

Jul. 02	Novavax Seeks Health Canada Approval for Updated Covid-19 Vaccine	MT
Jul. 02	Novavax: Health Canada approves Covid 24/25 vaccine	CF

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	May. 23	MT
Novavax Stockholder Shah Capital Withdraws Campaign Against Reelection of Directors	May. 20	MT
Shah Capital withdraws campaign against three Novavax directors	May. 20	RE
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; AMC Entertainment, GameStop to Advance	May. 14	MT
Novavax Stock Price More Than Doubles After COVID-19 Vaccine Licensing Deal With Sanofi	May. 10	MT
HEDGE FUND SHAH CAPITAL SAYS NOVAVAX-SANOFI DEAL IS "A STEP IN T…	May. 10	RE
HEDGE FUND SHAH CAPITAL - NOVAVAX-SANOFI DEAL CONCURS WITH SHAH…	May. 10	RE
Novavax's Shareholder Shah Capital Urges Vote Against Re-Election of Directors	May. 06	MT
Novavax's top shareholder Shah Capital ramps up efforts for board shakeup	May. 06	RE
Shah Capital urges Novavax shareholders to vote against three directors	May. 06	RE
Novavax investor Shah Capital to vote against three directors	May. 06	RE
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	Apr. 15	MT
Hedge fund Shah Capital urges Novavax board shake-up, FT says	Apr. 15	RE
Hedge fund Shah Capital urges board shake-up at Novavax over struggling Covid vaccine, FT reports	Apr. 15	RE
HC Wainwright Cuts Price Target on Novavax to $19 From $35, Keeps Buy Rating	Mar. 01	MT
B. Riley Trims Novavax's PT to $11 From $12 After Reaching Settlement on Gavi Arbitration Dispute, Keeps Buy Rating	Feb. 23	MT
Novavax: green light for updated Covid vaccine in Sweden	Dec. 14	CF
B. Riley Lowers Novavax's Price Target to $12 From $15 After Near-Term COVID-19 Sales Estimate Revisions, Maintains Buy Rating	Nov. 10	MT
B. Riley Upgrades Novavax to Buy From Neutral After Above-Consensus Q2 Beat, Says Turnaround Progressing; Retains $15 PT	23-08-09	MT
B. Riley Raises Novavax's PT to $15 From $10, Says Q1 Financial Update 'Not As Bad As Feared'; Keeps Neutral Rating	23-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Novavax Surges on $1.2 Billion Sanofi Vaccine Deal

May 10, 2024 at 02:52 pm EDT